<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269252</url>
  </required_header>
  <id_info>
    <org_study_id>USA710-4003</org_study_id>
    <nct_id>NCT04269252</nct_id>
  </id_info>
  <brief_title>CHI-907 CBD Extract and Experiences of Test Anxiety</brief_title>
  <official_title>A Randomized Controlled Test of the Effects of CHI-907 on Experiences of Test Anxiety Among College Students</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canopy Growth Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Madison University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canopy Growth Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled study examining the effects of CHI-907 on test&#xD;
      anxiety specifically, and state anxiety more broadly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment challenges due to COVID&#xD;
  </why_stopped>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal single-dose of CHI-907 to reduce test anxiety</measure>
    <time_frame>The test session visit is 3.5 hours long.</time_frame>
    <description>Subjects will report their level of test anxiety using the State Test Anxiety Visual Analog Scale (STAI-VAS) pre-test, mid-test, and post-test. The STAI-VAS is a measure from 0 (not anxious at all) to 100 (anxious).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal single-dose of CHI-907 to reduce test anxiety</measure>
    <time_frame>The test session visit is 3.5 hours long.</time_frame>
    <description>Subjects will report their level of test anxiety using the State Test Anxiety Visual Analog Scale (STAI-VAS) pre-test, mid-test, and post-test. The STAI-VAS is a measure from 0 (not anxious at all) to 100 (anxious).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>CHI-804 at 6 mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard 6 mL dose of placebo oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHI-907 at 1.5 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to receive one dose of CHI-907.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHI-907 at 3 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to receive one dose of CHI-907.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHI-907 at 6 mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to receive one dose of CHI-907.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHI-907</intervention_name>
    <description>CHI-907 is a high CBD extract.</description>
    <arm_group_label>CHI-907 at 1.5 mL</arm_group_label>
    <arm_group_label>CHI-907 at 3 mL</arm_group_label>
    <arm_group_label>CHI-907 at 6 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHI-804</intervention_name>
    <description>CHI-804 is the placebo formulation.</description>
    <arm_group_label>CHI-804 at 6 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult between 18 and 55-years-old (inclusive).&#xD;
&#xD;
          2. Willing and able to provide informed consent and attend a 2.5 hour, in-person session.&#xD;
&#xD;
          3. Self-reports completing a college-level introductory level statistics class with a&#xD;
             grade of &quot;C&quot; or better.&#xD;
&#xD;
          4. Scores a 3.0 or higher on the Westside Test Anxiety Scale.&#xD;
&#xD;
          5. Female of childbearing potential must not be pregnant or currently breastfeeding.&#xD;
&#xD;
          6. If using medication, the student has maintained a stable regimen on existing&#xD;
             medications for at least one month prior to participation in the study and throughout&#xD;
             the study.&#xD;
&#xD;
          7. Agrees to abide by all study restrictions and comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of significant allergic condition, significant hypersensitivity to the&#xD;
             IP, or allergic reaction to cannabis, cannabinoid medications, or excipients of the&#xD;
             investigational product.&#xD;
&#xD;
          2. Exposed to any investigational drug or device &lt; 30 days prior to screening or plans to&#xD;
             take an investigational drug in the near future.&#xD;
&#xD;
          3. Used cannabis, synthetic cannabinoid or cannabinoid analogue, synthetic cannabinoid&#xD;
             receptor agonist, or any CBD- or THC-containing product within 30 days of screening or&#xD;
             during the study.&#xD;
&#xD;
          4. Current or past primary DSM-5 diagnosis other than an anxiety disorder that the&#xD;
             Investigator determines would interfere in testing or interfere in evaluation of the&#xD;
             study testing.&#xD;
&#xD;
          5. Total score of 8 or higher on the Alcohol Use Disorders Identification Test.&#xD;
&#xD;
          6. Total score of 12 or higher on the Drug Abuse Screening Test.&#xD;
&#xD;
          7. An acute or progressive disease that is likely to require changes in drug therapy&#xD;
             during the study, or interfere with the objectives of the study, or the ability to&#xD;
             adhere to protocol requirements.&#xD;
&#xD;
          8. Currently prescribed medications with likely THC- or CBD- interactions.&#xD;
&#xD;
          9. History of suicide attempt in the last year.&#xD;
&#xD;
         10. Endorses current suicidal intent during the baseline assessment.&#xD;
&#xD;
         11. Positive drug screen for THC, barbiturates, amphetamines, benzodiazepines, and/or&#xD;
             opiates at baseline assessment.&#xD;
&#xD;
         12. Clinically significant condition or abnormal findings during screening or the baseline&#xD;
             assessment that would, in the opinion of the Investigator, preclude study&#xD;
             participation or interfere with the evaluation of the study testing.&#xD;
&#xD;
         13. Demonstrates behavior indicating unreliability or inability to comply with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
         14. Female student of childbearing potential, unless willing to ensure that they or their&#xD;
             partner use effective contraception during the study and for three months thereafter.&#xD;
&#xD;
         15. Male student whose partner is of childbearing potential, unless willing to ensure that&#xD;
             they or their partner use effective contraception during the study and for three&#xD;
             months thereafter.&#xD;
&#xD;
         16. Any other significant disease or disorder which, in the opinion of the investigator,&#xD;
             may either put the student at risk because of participation in the study, may&#xD;
             influence the result of the study, or affect the student's ability to participate in&#xD;
             the study.&#xD;
&#xD;
         17. History of diagnosis related to hepatic function and/or significantly impaired hepatic&#xD;
             function (alanine aminotransferase [ALT] &gt;5 ´ upper limit of normal [ULN] or total&#xD;
             bilirubin [TBL] &gt;2 ´ ULN) OR the ALT or aspartate aminotransferase (AST) &gt;3 ´ ULN and&#xD;
             TBL &gt;2 ´ ULN (or international normalized ratio [INR] &gt;1.5).&#xD;
&#xD;
         18. Plans for the student to travel outside their country of residence during the study.&#xD;
&#xD;
         19. Body mass index (BMI) of underweight (18 kg/m2 and below) or obese (30 kg/m2 and&#xD;
             above) or waist:hip ratio that is considered high health risk (0.86 and higher for&#xD;
             women, 1.0 and higher for men).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ware, MD</last_name>
    <role>Study Director</role>
    <affiliation>Canopy Growth Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Madison University</name>
      <address>
        <city>Harrisonburg</city>
        <state>Virginia</state>
        <zip>22807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Test Anxiety</keyword>
  <keyword>CBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

